KORU Medical Systems, Inc. (KRMD) is a publicly traded company in the Healthcare — Medical - Instruments & Supplies industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
KORU Medical Systems, Inc. is dedicated to the development, manufacturing, and commercialization of mobile medical devices, primarily serving the ambulatory infusion market across both the United States and international territories. The company's primary offerings revolve around mechanical infusion solutions, notably their FREEDOM infusion systems.
Analysis Summary
KORU Medical Systems, Inc. reported revenue of $41.1M in the most recent fiscal year, growing at a 5-year CAGR of 11.2%.
Trailing-twelve-month margins: gross margin 62.0%, operating margin -3.7%, net margin -4.0%.
At the current price of $3.22, KRMD has negative trailing earnings (P/E not meaningful) and an ROE of -10.63%. Market capitalisation stands at $148M.
Balance sheet quality for KRMD: current ratio of 2.4, net cash position of $5.4M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $3.22 |
| Market Cap | $148M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 8.02 |
| EV / EBITDA | -140.34 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -10.63% |
| Return on Invested Capital | -7.74% |
| Return on Assets | -6.51% |
| Gross Margin | 61.99% |
| Operating Margin | -3.66% |
| Net Margin | -4.03% |
Financial Health
| Debt / Equity | 0.18 |
| Current Ratio | 2.72 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| KRMD | KORU Medical Systems, Inc. | $148M | 8.02 | -10.6% | |
| 0R29.L | Intuitive Surgical, Inc. | $137.6B | 74.97 | 12.01 | 17.8% |
| ISRG | Intuitive Surgical, Inc. | $135.5B | 44.28 | 7.65 | 17.8% |
| 0R19.L | Becton, Dickinson and Company | $52.3B | 33.07 | 2.18 | 6.6% |
| BDX | Becton, Dickinson and Company | $50.0B | 55.98 | 2.09 | 3.8% |
| RMD | ResMed Inc. | $33.1B | 22.82 | 5.24 | 23.9% |
| 0KW4.L | ResMed Inc. | $32.5B | |||
| MDLN | Medline Inc. | $27.2B | 37.72 | 2.40 | 10.8% |
Price Performance
| 1 month | -3.01% |
| 3 months | -17.44% |
| Year-to-date | -44.58% |
| 1 year | -20.30% |
| 3 years | +13.78% |
52-Week Range
| 52-week High | $6.61 |
| 52-week Low | $3.09 |
| Avg Volume (90d) | 179K |
Related companies: HIND · INFU · MXCT · NYXH · OSUR · PRE · PROF
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of KRMD: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks